Future in vitro and in vivo studies are warranted to determine whether mentioned drugs (such as DRD2 antagonists, MAPK12 inhibitors, RET inhibitors, or drugs targeting PTN) can inhibit tumor growth and improve survival and quality of life in dogs with PPGL. The gene discussed is DRD2; the disease is neoplasm.